A New Oral Psoriasis Treatment

SOTYKTU™ (deucravacitinib tablets) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

SOTYKTU demonstrated superior response rates vs. apremilast and placebo at Week 16[1,2]

In the POETYK PSO-1 clinical trial*, SOTYKTU demonstrated significantly higher PASI 75 and PASI 90 response rates vs. apremilast at Weeks 16 and 24 (secondary endpoints)



†Co-primary endpoint SOTYKTU vs. placebo
‡$p \leq 0.0001$ SOTYKTU vs. placebo or SOTYKTU vs. apremilast

Adapted from Product Monograph and Armstrong *et al*., 2022.



†$p<0.001$ SOTYKTU vs. apremilast
‡$p \leq 0.0001$ SOTYKTU vs. placebo or SOTYKTU vs. apremilast

Adapted from Product Monograph and Armstrong *et al*., 2022.

ONCE-DAILY
SOTYKTU™
deucravacitinib tablets

SOTYKTU demonstrated significantly higher sPGA 0/1 response rates vs. apremilast at Weeks 16 and 24 (secondary endpoints)[1]



†Co-primary endpoint SOTYKTU vs. placebo
‡$p \leq 0.0001$ SOTYKTU vs. placebo or SOTYKTU vs. apremilast

Adapted from Product Monograph and Armstrong *et al.*, 2022.

Learn more at SOTYKTU.CA

Clinical Use:
There are no data in pediatric patients, therefore, Health Canada has not authorized an indication for pediatric use.

Relevant Warnings and Precautions:
- No studies on the effects of SOTYKTU on ability to drive and use machinery. Exercise caution when driving or operating a vehicle or potentially dangerous machinery.
- Contains lactose. SOTYKTU should not be administered in patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.
- Increased risk of infections. SOTYKTU should not be initiated in patients with any clinically important active infection until it resolves or is adequately treated.
- Pre-treatment evaluation of tuberculosis (TB). Do not administer SOTYKTU to patients with active TB.
- Avoid use of live vaccines with SOTYKTU. The response to live or non-live vaccines has not been evaluated.
- Insufficient data to inform on risk in pregnant women.
- It is unknown if SOTYKTU is excreted in human milk. Precaution should be exercised because many drugs can be excreted in human milk.
- Not recommended in patients with severe hepatic impairment (Child-Pugh Class C).

For More Information:
Please consult the Product Monograph at https://www.bms.com/assets/bms/ca/documents/productmonograph/SOTYKTU_EN_PM.pdf for adverse reactions, drug interactions, and dosing information. The Product Monograph is also available by calling 1-866-463-6267.

PASI=Psoriasis Area and Severity Index; sPGA=static Physician's Global Assessment
*Phase 3, 52-week, multi-centre, double-blind, randomized, placebo- and active comparator-controlled study in adults with moderate-to-severe plaque psoriasis to compare SOTYKTU 6 mg QD (n=332), apremilast 30 mg BID (n=168), and placebo (n=166).[1,2]

References:
1. SOTYKTU Product Monograph. Bristol-Myers Squibb Canada Co. November 23, 2022.
2. Armstrong AW, Gooderham M, Warren RB, *et al.* Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. *JAAD*. 2022. doi: 10.1016/j.jaad.2022.07.002
3. Armstrong AW, Gooderham M, Warren RB, *et al.* Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. *JAAD*. 2022. doi: 10.1016/j.jaad.2022.07.002 Suppl

Bristol Myers Squibb™

1787-CA-2300029E

ONCE-DAILY
SOTYKTU™
deucravacitinib tablets